Clinical Innovator Award
Clinical Innovator Award supports researchers conducting early-phase immunotherapy trials in chordoma, funding clinical investigation to move promising concepts toward potential patient impact.
Browse similar grants
Funder: Chordoma Foundation
Due Dates: December 1, 2026 (Initial application)
Funding Amounts: Up to $1 million USD per clinical trial
Summary: Supports early-phase clinical trials translating promising immunotherapy concepts into potential patient impact in chordoma.
Key Information: Delivered through the Cancer Research Institute’s Clinical Innovator program; consult CRI for applicant requirements and award terms.
Description
The Chordoma Foundation offers this award through its ongoing collaboration with the Cancer Research Institute (CRI) to accelerate innovative immunotherapy research in chordoma. Delivered through CRI’s Clinical Innovator program, the award focuses on early-phase clinical trials that move promising immunotherapy concepts into clinical investigation and toward patient impact.
This opportunity supports immunotherapy-focused clinical work, rather than the broader preclinical research and research infrastructure supported by the Foundation. Its clinical trial funding is distinct from the Foundation’s other resources, including disease models, biospecimens, preclinical capabilities, and clinical trial assistance. Those services are separate from the funding commitments under this award.
